AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia
Shakti P Pattanayak, Odai Darawshi, Omid Hajihassani, Jordan M Winter, Nicole Weiler, Melanie Ott, Florian Rothweiler, Jindrich Cinatl, Martin Michaelis, Daniel J Lindner, Thomas D Green, Polina Krassovskaia, Raphael T Aruleba, Kelsey H Fisher-Wellman, Jason A Mears, David Wald, Leif A Eriksson, Boa · 2026
Read AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia by Shakti P Pattanayak, Odai Darawshi, Omid Hajihassani, Jordan M Winter, Nicole Weiler, Melanie Ott, Florian Rothweiler, Jindrich Cinatl, Martin Michaelis, Daniel J Lindner, Thomas D Green, Polina Krassovskaia, Raphael T Aruleba, Kelsey H Fisher-Wellman, Jason A Mears, David Wald, Leif A Eriksson, Boa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13436024.txt.
Description
Shakti P Pattanayak's team built AcTor in 2026, a first-of-its-kind stimulator of the mTOR pathway, to boost the leukemia drug ixazomib. Blocking mTOR can shield cancer cells during chemotherapy, so the team reasoned the opposite, activating mTOR by blocking its brake, TSC2, might sensitize cells to proteasome blockade. Computer docking and chemistry produced AcTor, tested alone and with ixazomib across leukemia lines and patient samples.
The pair collapsed mitochondrial energy, raised reactive oxygen, and drove cell death, with stronger effects in drug-resistant leukemia, and it shrank disease and stem-like cells in mice, including a TP53-mutant model. The authors warn AcTor must not be used alone in cancer. Leukemia teams get a counterintuitive combination strategy with animal proof, awaiting human safety data.
Catalog record
| CREATOR | Shakti P Pattanayak, Odai Darawshi, Omid Hajihassani, Jordan M Winter, Nicole Weiler, Melanie Ott, Florian Rothweiler, Jindrich Cinatl, Martin Michaelis, Daniel J Lindner, Thomas D Green, Polina Krassovskaia, Raphael T Aruleba, Kelsey H Fisher-Wellman, Jason A Mears, David Wald, Leif A Eriksson, Boa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |